|
Chronic Myeloid Leukemia: How to Treat During Pregnancy |
0.25 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
The Role of JAK Inhibitors in the Management of Myelofibrosis |
0.50 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
CAR T-Cell Therapies in Hematologic Malignancies: Challenges and Strategies |
1.00 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Optimizing the Use of Bispecific Antibodies in Hematologic Malignancies |
1.00 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Managing Earlier Integration of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia |
0.75 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Review of Oral Targeted Therapies in Acute Myeloid Leukemia |
0.75 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Myelodysplastic Syndromes: Treatment Updates and Emerging Data |
0.50 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Management of Multiple Myeloma: Smoldering, Newly Diagnosed, and Relapsed/Refractory Disease |
2.25 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Managing Post-Treatment Complications for Multiple Myeloma and Acute Lymphocytic Leukemia |
1.00 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Debate: Is the Addition of Polatuzumab Vedotin the New Standard First-Line Therapy for Diffuse Large B-Cell Lymphoma? |
0.75 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Diffuse Large B-Cell Lymphoma: Sequencing Therapy for Relapsed/Refractory Disease |
0.50 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Updates in Prognosis and Treatment |
1.00 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
What is Optimal First-Line Management of Advanced Classic Hodgkin Lymphoma? |
0.75 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
|
NCCN Guidelines® Insights - Survivorship, Version 2.2024 |
1.00 |
12/10/2024 - 12:00am to 12/10/2025 - 12:00am |
|
Unraveling Cancer Pain Dynamics |
1.00 |
12/16/2024 - 12:00am to 10/31/2025 - 11:59pm |
Facebook
Twitter
LinkedIn
Forward